Evidence map›Paper›PMID 38280960›Full record

ArticleAnnals of surgical oncology2024

ASO Author Reflections: Using a CA19-9 Tumor Marker Gene Test to Assess Outcome after Pancreatic Cancer Surgery.

Yohei Ando, Michael Goggins

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yohei AndoDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Michael GogginsDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. mgoggins@jhmi.edu.

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
Using markers to improve pancreatic cancer screening and surveillance: a multi-center studyU01CA210170 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael G. Goggins · 2016 to 2026
$9.3M
Using Markers to Improve Pancreatic Cancer ScreeningR01CA176828 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2013 to 2024
$4.1M
Division of Cancer Prevention, National Cancer Institute CA176828Division of Cancer Prevention, National Cancer Institute CA 210170Division of Cancer Prevention, National Cancer Institute CA62924
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CA-19-9 AntigenPancreatic NeoplasmsBiomarkers, TumorHumansPancreasBiomarkers, TumorCA-19-9 Antigen

Identifiers

PMID38280960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.